Notice2023-20390
Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 21, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a meeting on November 16, 2023. The topic for this meeting will be "The Application of Digital Health Technology to Type 2 Diabetes Management: Current Status, Research Gaps, and Opportunities". The meeting is open to the public.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 182 (Thursday, September 21, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 182 (Thursday, September 21, 2023)]
[Notices]
[Pages 65184-65185]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-20390]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency Coordinating Committee
Meeting
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Diabetes Mellitus Interagency Coordinating Committee
(DMICC) will hold a meeting on November 16, 2023. The topic for this
meeting will be ``The Application of Digital Health Technology to Type
2 Diabetes Management: Current Status, Research Gaps, and
Opportunities''. The meeting is open to the public.
DATES: The meeting will be held on November 16, 2023 from 12:00 p.m. to
4:00 p.m. EST.
ADDRESSES: The meeting will be held via the Zoom online video
conferencing platform. For details, and to register, please contact
<a href="/cdn-cgi/l/email-protection#e2868f8b8181a28f838b8ecc8c8b8acc858d94"><span class="__cf_email__" data-cfemail="1d7970747e7e5d707c747133737475337a726b">[email protected]</span></a>.
FOR FURTHER INFORMATION CONTACT: For further information concerning
this meeting, including a draft agenda, which will be posted when
available, see the DMICC website, <a href="http://www.diabetescommittee.gov">www.diabetescommittee.gov</a>, or contact
Dr. William Cefalu, Executive Secretary of the Diabetes Mellitus
Interagency Coordinating Committee, National Institute of Diabetes and
Digestive and Kidney Diseases, 6707 Democracy Boulevard, Democracy 2,
Room 6037, Bethesda, MD 20892, telephone: 301-435-1011; email:
<a href="/cdn-cgi/l/email-protection#e98d84808a8aa984888085c7878081c78e869f"><span class="__cf_email__" data-cfemail="8de9e0e4eeeecde0ece4e1a3e3e4e5a3eae2fb">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In accordance with 42 U.S. Code 285c-3, the
DMICC, chaired by the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) comprising members of the Department of Health
and Human Services and other federal agencies that support diabetes-
related
[[Page 65185]]
activities, facilitates cooperation, communication, and collaboration
on diabetes among government entities. DMICC meetings, held several
times a year, provide an opportunity for Committee members to learn
about and discuss current and future diabetes programs in DMICC member
organizations and to identify opportunities for collaboration. The
November 16, 2023 DMICC meeting will focus on ``The Application of
Digital Health Technology to Type 2 Diabetes Management: Current
Status, Research Gaps, and Opportunities.''
Any member of the public interested in presenting oral comments to
the Committee should notify the contact person listed on this notice at
least 5 days in advance of the meeting. Interested individuals and
representatives or organizations should submit a letter of intent, a
brief description of the organization represented, and a written copy
of their oral presentation in advance of the meeting. Only one
representative of an organization will be allowed to present; oral
comments and presentations will be limited to a maximum of 5 minutes.
Printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
Committee by forwarding their statement to the contact person listed on
this notice. The statement should include the name, address, telephone
number and when applicable, the business or professional affiliation of
the interested person. Because of time constraints for the meeting,
oral comments will be allowed on a first-come, first-serve basis.
Members of the public who would like to receive email notification
about future DMICC meetings should register for the listserv available
on the DMICC website, <a href="http://www.diabetescommittee.gov">www.diabetescommittee.gov</a>.
William T. Cefalu,
Director, Division of Diabetes, Endocrinology, and Metabolic Diseases,
National Institute of Diabetes and Digestive and Kidney Diseases, and
Metabolic Diseases, National Institutes of Health.
[FR Doc. 2023-20390 Filed 9-20-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 21, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.